Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-06-17 20:47:09 ET · period of report 2026-06-15 · accession 0001628280-26-044083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-17 20:47 | 2026-06-15 | ARQT | LIN SUE-JEAN | Dir | S - Sale | $24.38 | -4,946 | 27.6K | -15% | -$120.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | S | D | 4,946 | $24.38 | 27,567 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |